Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Samsung Medical Center | OTHER |
| Inje University Haeundae Paik Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this multicenter observational study is to determine whether preoperative statin use reduces major adverse cardiovascular events or other complications after liver transplantation. The main question it aims to answer is:
Does preoperative statin use reduce major adverse cardiovascular events or other complications after liver transplantation? The records of participants who already took statins before liver transplantation will be reviewed.
Cardiovascular complications have emerged as a leading cause of early postoperative death following liver transplantation (LT), accounting for over 40% of early deaths. As a result, preventing postoperative cardiac complications has become a critical concern in the management of LT recipients.
Statin therapy has been suggested to improve perioperative and long-term outcomes in various surgical populations, primarily through LDL cholesterol reduction as well as pleiotropic effects, such as enhanced endothelial function and anti-inflammatory actions. However, evidence specifically examining the impact of preoperative statin therapy on cardiovascular outcomes after LT remains limited, highlighting the need for further research in this population.
This study aimed to address the current knowledge gap by investigating the association between preoperative statin use and the incidence of major adverse cardiovascular events within 30 days after liver transplantation in liver transplant recipients. Secondary outcomes included overall mortality, graft failure, early allograft dysfunction, acute kidney injury, and length of stay in the intensive care unit.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control group | Patients who did not receive preoperative statin therapy | ||
| Statin group | Patients who received preoperative statin therapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Preoperative Statin Use | Drug | Administration of any statin medication prior to liver transplantation. Statin therapy was previously prescribed by the treating physician before the transplant procedure, not assigned by the study protocol. |
| Measure | Description | Time Frame |
|---|---|---|
| 30-day Major Adverse Cardiovascular Events | The composite of cardiovascular death, heart failure, myocardial infarction, atrial fibrillation, ventricular arrhythmia, ischemic electrocardiogram changes (ST-segment depression or elevation) with chest tightness, pulmonary embolism, and stroke | 30 days after liver transplantation |
| Measure | Description | Time Frame |
|---|---|---|
| Acute Kidney Injury | Occurrence of acute kidney injury within 7 days post-transplantation, diagnosed according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria | Within 7 days after liver transplantation |
| Early Allograft Dysfunction |
Not provided
Inclusion Criteria:
- Adult patients aged ≥18 years who underwent liver transplantation
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients (≥18 years) who underwent liver transplantation at Asan Medical Center, Samsung Medical Center, and Inje University Haeundae Paik Hospital in Korea between January 2008 and January 2026.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asan Medical Center | Seoul | 05505 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019161 | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| ID | Term |
|---|---|
| D000924 | Anticholesteremic Agents |
| D000960 | Hypolipidemic Agents |
| D000963 | Antimetabolites |
| D045504 | Molecular Mechanisms of Pharmacological Action |
Not provided
Not provided
Not provided
Not provided
Not provided
|
Defined as serum bilirubin >10 mg/dL or international normalized ratio (INR) >1.6 on postoperative day (POD) 7, or alanine/aspartate aminotransferases >2000 IU/L within 7 days after transplantation
| Within 7 days after liver transplantation |
| Intensive Care Unit Length of Stay | Total duration (days) of intensive care unit stay after liver transplantation | From the date of liver transplantation until intensive care unit discharge, up to 600 days |
| Overall Mortality | Death from any cause after liver transplantation | From the date of liver transplantation to Mar 22, 2026 |
| Overall Graft Failure | Recipient death or retransplantation for any cause | From the date of liver transplantation to Mar 22, 2026 |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D004791 | Enzyme Inhibitors |
| D057847 | Lipid Regulating Agents |
| D045506 | Therapeutic Uses |